论文部分内容阅读
目的探讨脑梗死急性期口服不同剂量阿托伐他汀对患者临床康复预后的影响。方法回顾性分析356例脑梗死患者的临床资料,根据患者住院期间口服阿托伐他汀剂量进行分组,20 mg组153例,40 mg组137例,60 mg组19例,80 mg组47例,比较分析各组患者的人口学资料、脑血管病危险因素分布及主要危险因素控制用药种类分布和NIHSS评分。结果各组患者人口学资料、脑血管病危险因素分布和主要危险因素控制用药种类分布差异无统计学意义。组间NIHSS评分有效率差异有统计学意义(χ~2=8.041,P=0.045),应用卡方分割法进一步检验,显示20~40 mg组与60~80 mg组NIHSS评分有效率差异具有显著性(有效率分别为32.76%、50.00%,χ~2=6.941,P=0.008)。Logistic回归分析显示阿托伐他汀剂量为急性脑梗死临床康复预后的独立影响因素,OR值为1.382,95%可信区间1.111~1.719,P=0.004。结论脑梗死急性期应用高剂量阿托伐他汀对于改善患者康复预后具有更好的促进作用。
Objective To investigate the effects of different doses of atorvastatin on the prognosis of patients after acute cerebral infarction. Methods The clinical data of 356 patients with cerebral infarction were retrospectively analyzed. According to the dose of oral atorvastatin during hospitalization, 153 patients in 20 mg group, 137 in 40 mg group, 19 in 60 mg group and 47 in 80 mg group were retrospectively analyzed. The demographic data, the distribution of risk factors of cerebrovascular disease and the distribution of controlled drugs and the NIHSS scores of major risk factors were compared among the groups. Results There was no significant difference in demographic data, distribution of risk factors of cerebrovascular disease and the distribution of the main risk factors among the controlled drugs in each group. NIHSS scores between groups were statistically significant (χ ~ 2 = 8.041, P = 0.045), and further tests using chi-square test showed that 20 ~ 40 mg and 60 ~ 80 mg NIHSS score effective rate was significantly different (Effective rate was 32.76%, 50.00%, χ ~ 2 = 6.941, P = 0.008). Logistic regression analysis showed that the dose of atorvastatin was an independent influencing factor in the prognosis of acute cerebral infarction. The OR was 1.382, 95% confidence interval 1.111-1.719, P = 0.004. Conclusions The use of high-dose atorvastatin in the acute stage of cerebral infarction has a better effect on improving the prognosis of patients.